Healthcare consumer confidence on a decline
ANN ARBOR, Mich. — The healthcare-reform bill promised to dramatically expand coverage for Americans, but healthcare consumer confidence hasn’t necessarily kept up, according to data released Monday by Thomson Reuters.
When Thomson Reuters started the Consumer Healthcare Sentiment Index in December 2009, it had a baseline measurement of 100; that number fell to 95 by July but rebounded to 100 in September. But it fell to 97 and then 96 in October and November, respectively. The index is updated monthly, is based on the Thomson Reuters "PULSE Healthcare Survey" and has two parts, a retrospective component based on respondents’ experiences during the past three months and a prospective component based on their expectations over the next three months.
While fewer respondents said they delayed or canceled healthcare treatment over the past three months, they appeared more likely to do so over the next three months. The low number in November came as more respondents predicted they would cancel doctor visits, diagnostic tests and therapies, and postpone filling prescriptions.
Lilly donates grant to Manchester College for pharmacy school
FORT WAYNE, Ind. — Manchester College has received a $35 million grant from the Lilly Endowment to launch a new school of pharmacy.
Manchester College, a college of 1,278 students affiliated with the Church of the Brethren and based in North Manchester, Ind., said the grant would allow it to develop its first doctoral program on a campus in the nearby city of Fort Wayne, Ind. The Lilly Endowment was founded in 1937 with stock in Indianapolis-based drug maker Eli Lilly.
“We are pleased to offer this funding to Manchester College to assist it in establishing its new school of pharmacy,” Lilly Endowment VP education Sara Cobb said. “The school will further important efforts in Indiana to increase opportunities for education and careers in the [science, technology, engineering and mathematics] disciplines.”
King, Acura seek regulatory approval for Acurox
BRISTOL, Tenn. — Drug makers King Pharmaceuticals and Acura Pharmaceuticals have submitted a regulatory approval application to the Food and Drug Administration for an opioid pain reliever.
The two drug makers announced Tuesday the submission for Acurox (oxycodone hydrochloride), an immediate-release tablet for relief of moderate to severe pain.
The tablets use Acura’s aversion technology, designed to deter abuse of the drug by dissolving or crushing the pills.